Last reviewed · How we verify

SOLUBIOMIX — Portfolio Competitive Intelligence Brief

SOLUBIOMIX pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Daypro Oxaprozin marketed Nonsteroidal Anti-inflammatory Drug [EPC] Prostaglandin G/H synthase 1 Immunology 1992-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ANI Pharmaceuticals · 1 shared drug class
  2. Assiut University · 1 shared drug class
  3. Boehringer Ingelheim · 1 shared drug class
  4. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
  5. Centro Hospitalar Lisboa Ocidental · 1 shared drug class
  6. Dartmouth-Hitchcock Medical Center · 1 shared drug class
  7. Dr. Reddy's Laboratories Limited · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SOLUBIOMIX:

Cite this brief

Drug Landscape (2026). SOLUBIOMIX — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/solubiomix. Accessed 2026-05-14.

Related